{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:22:27Z","timestamp":1694611347130},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1681","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved zavegepant nasal spray (Zavzpret \u2013 Pfizer) for acute treatment of migraine with or without aura in adults. Zavzpret is the first nasal spray formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist (\u201cgepant\u201d) to become available in the US.<\/jats:p>","DOI":"10.58347\/tml.2023.1681c","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T15:45:22Z","timestamp":1694533522000},"page":"116-118","source":"Crossref","is-referenced-by-count":0,"title":["Zavegepant (Zavzpret) for Acute Treatment of Migraine"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,7,24]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T15:45:23Z","timestamp":1694533523000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1681c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":0,"journal-issue":{"issue":"1681","published-online":{"date-parts":[[2023,7,24]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1681c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}